The Star Entertainment Group Limited (ASX:SGR) Addresses Media Speculation on DBC Equity Disposal
The Star Entertainment Group (ASX:SGR) addresses media speculation on the potential sale of its 50% equity in Destination Brisbane Joint Venture.
Tag: Mergers & Acquisitions
Insignia Financial Ltd (ASX:IFL) Receives Revised Acquisition Proposals
Insignia Financial Ltd (ASX:IFL) receives increased acquisition proposals of A$5.00 per share from Bain Capital and CC Capital.
Rio Tinto (ASX:RIO) Completes $6.7 Billion Acquisition of Arcadium Lithium
Rio Tinto (ASX:RIO) completes its $6.7 billion acquisition of Arcadium Lithium, expanding its position as a global leader in lithium production.
Blackstone Minerals (ASX:BSX) Announces Visible Gold Discovery and Merger with IDM
Blackstone Minerals (ASX:BSX) announces visible gold discovery at Mankayan Project and a strategic merger with IDM International to enhance growth prospects.
BlueBet Holdings Ltd (ASX:BBT) Proposes Superior Offer to Acquire PointsBet
BlueBet Holdings Ltd (ASX:BBT) proposes a superior offer to acquire PointsBet, offering a 45% premium and $40m in cost synergies.
Eureka Group Holdings Limited (ASX:EGH) Acquires Second All-Age Rental Village
Eureka Group Holdings (ASX:EGH) acquires Tuggerah Shores Home Village on NSW Central Coast, expanding its all-age rental portfolio with an 8.6% yield.
Quickstep Holdings (ASX:QHL) Agrees to 44% Premium Acquisition by ASDAM
Quickstep Holdings (ASX:QHL) to be acquired by ASDAM Operations at a 44% premium pending shareholder vote.
Astral Resources (ASX:AAR) Reports Outstanding Gold Recoveries and Progress on Maximus Takeover
Astral Resources (ASX:AAR) reports a 98.2% gold recovery at Theia Deposit and progresses the takeover of Maximus Resources.
Clean Seas Seafood (ASX:CSS) Announces 1H FY25 Results
Clean Seas Seafood (ASX:CSS) reports a 10.4% revenue decline in 1H FY25 and announces a potential merger with Yumbah Aquaculture.
The Hydration Pharmaceuticals Company Limited (ASX:HPC) Reports FY2024 Financial Results
The Hydration Pharmaceuticals Company Limited (ASX:HPC) reports a 25.5% revenue decline in FY2024, asset divestiture, and a strategic focus on US growth.